Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced ...

LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has granted inducement awards to seven newly hired employees as a means to attract ...

LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (SVRA) (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards ...

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to seven new employees. On April 9 ...

Savara (SVRA) “announced encore presentations of top-line data from the pivotal, Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP will ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has entered into a loan and security agreement ...

LANGHORNE, Pa. - Savara Inc. (NASDAQ:SVRA), a biopharmaceutical company specializing in rare respiratory diseases with a market capitalization of $574.6 million, is set to present data from a ...

Savara has a one year low of $2.26 and a one year high of $5.34. The business’s 50-day moving average price is $2.72 and its two-hundred day moving average price is $3.26.

Savara Inc, a pharmaceutical company currently valued at $612 million, announced today that it has terminated its material definitive agreement with Evercore Group L.L.C., effectively ending their ...